Positive 'Restless Legs' Data Send XenoPort Shares Soaring April 26, 2007 By Jennifer Boggs Shares of XenoPort Inc. leaped 44 percent on news that its gabapentin prodrug, XP13512, met its endpoints in the first of three Phase III studies in restless legs syndrome (RLS). (BioWorld Today)Read More
RSS